In 1998, Proleukin® (Aldesleukin, human recombinant IL-2) was approved by the FDA for use at a sustained high dose in patients with metastatic renal cell carcinoma (MRCC) or metastatic melanoma (MM) (4, 5). This evidence concerns the gene IL2 and Miyoshi myopathy.